1. Home
  2. SCLX vs NRSN Comparison

SCLX vs NRSN Comparison

Compare SCLX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • NRSN
  • Stock Information
  • Founded
  • SCLX 2011
  • NRSN 2017
  • Country
  • SCLX United States
  • NRSN Israel
  • Employees
  • SCLX N/A
  • NRSN N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • NRSN Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCLX Health Care
  • NRSN Health Care
  • Exchange
  • SCLX Nasdaq
  • NRSN Nasdaq
  • Market Cap
  • SCLX 35.7M
  • NRSN 31.1M
  • IPO Year
  • SCLX N/A
  • NRSN 2021
  • Fundamental
  • Price
  • SCLX $18.73
  • NRSN $1.15
  • Analyst Decision
  • SCLX Strong Buy
  • NRSN Buy
  • Analyst Count
  • SCLX 3
  • NRSN 2
  • Target Price
  • SCLX $367.50
  • NRSN $14.00
  • AVG Volume (30 Days)
  • SCLX 309.9K
  • NRSN 1.3M
  • Earning Date
  • SCLX 08-13-2025
  • NRSN 09-17-2025
  • Dividend Yield
  • SCLX N/A
  • NRSN N/A
  • EPS Growth
  • SCLX N/A
  • NRSN N/A
  • EPS
  • SCLX N/A
  • NRSN N/A
  • Revenue
  • SCLX $44,236,000.00
  • NRSN N/A
  • Revenue This Year
  • SCLX $89.26
  • NRSN N/A
  • Revenue Next Year
  • SCLX $203.95
  • NRSN N/A
  • P/E Ratio
  • SCLX N/A
  • NRSN N/A
  • Revenue Growth
  • SCLX N/A
  • NRSN N/A
  • 52 Week Low
  • SCLX $3.60
  • NRSN $0.80
  • 52 Week High
  • SCLX $39.90
  • NRSN $2.60
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 46.04
  • NRSN 40.37
  • Support Level
  • SCLX $14.80
  • NRSN $1.12
  • Resistance Level
  • SCLX $30.90
  • NRSN $1.26
  • Average True Range (ATR)
  • SCLX 3.47
  • NRSN 0.07
  • MACD
  • SCLX -1.47
  • NRSN 0.01
  • Stochastic Oscillator
  • SCLX 23.68
  • NRSN 16.73

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: